Clinical Trial Update: Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update reports tolerability, safety, and health outcomes in relapsing multiple sclerosis and notes completion of the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Snippet

Sponsor: Novartis | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED